Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02531958 · ClinicalTrials.gov registry record · NA

Assessment of Optimal Egg Intake in a Healthy Population

A NA study, sponsored by University of Connecticut.

Completed
Registry status
NA
Development phase
38
Enrollment target

NCT02531958: Completed NA study, sponsored by University of Connecticut.

NCT02531958 is a NA study that has completed, run by University of Connecticut. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02531958, a NA study, has completed, sponsored by University of Connecticut.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target

Study Summary

Recently, the United States Department of Agriculture (USDA) has recommended removal of the 300mg/day limit on dietary cholesterol intake due to a lack of evidence supporting a connection between cholesterol intake and increased risk for cardiovascular disease (CVD). Previous work has shown that daily intake of eggs actually favorably alters many parameters associated with CVD risk. Conversely, emerging research suggests that choline, a nutrient in eggs, may be converted into trimethylamine oxide (TMAO) by the intestinal microbiota. TMAO is thought to increase the risk for CVD. Therefore, the purpose of this study is to determine a threshold of daily egg intake at which the risk for CVD is not negatively impacted in a young, healthy population.

Primary Outcome

Plasma HDL (in mg/dL) will be measured at 2, 6, 10, and 14 weeks to determine the impact of daily egg intake on HDL

Interventions

  • OTHER Eggs

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2015-08-14
Est. Completion 2017-05-31
Phase NA
University of Connecticut

107 total trials

What the finished NCT02531958 record still lists

NCT02531958 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which Eggs is the first listed.

NCT02531958 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02531958 about?

NCT02531958 is a clinical study titled "Assessment of Optimal Egg Intake in a Healthy Population". Recently, the United States Department of Agriculture (USDA) has recommended removal of the 300mg/day limit on dietary cholesterol intake due to a lack of evidence supporting a connection between cholesterol intake and increased risk for cardiovascular disease (CVD). Previous work has shown that dai...

What is the current status of trial NCT02531958?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2015-08-14. Estimated completion is 2017-05-31.

What interventions are being tested in trial NCT02531958?

The interventions under investigation include: Eggs (OTHER).

Who is sponsoring clinical trial NCT02531958?

This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02531958's enrollment target sits among peer trials

38 1538th of 2000 higher than 461 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02531958, the US trial registry maintained by the National Library of Medicine. NCT02531958 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.